异基因造血干细胞移植治疗儿童重型再生障碍性贫血相关并发症的临床研究
Clinical Study of Related Complications of Severe Aplastic Anemia Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
DOI: 10.12677/acm.2024.143940, PDF,   
作者: 王如民：石河子大学医学院，新疆 石河子；李雪国, 徐艳芳, 高 媛, 毛 敏, 郎 涛*：新疆维吾尔自治区人民医院血液科，新疆 乌鲁木齐
关键词: 异基因造血干细胞移植；儿童；并发症；重型再生障碍性贫血；Allogeneic Hematopoietic Stem Cell Transplantation； Children； Complication； Severe Aplastic Anaemia
摘要: 目的：分析异基因造血干细胞移植(allo-HSCT)治疗重型再生障碍性贫血(SAA)儿童后的并发症的临床特征。方法：分析2017.09~2023.05在新疆维吾尔自治区人民医院接受allo-HSCT的52名SAA儿童患者(≤14岁)的临床资料。结果：HID-HSCT和MSD-HSCT总生存率是没有统计学差异的(88.6% vs 100.0%，P = 0.154)。最常见的并发症是移植物抗宿主病(GVHD)，分别有14例(26.9%)和9例(17.3%)患者发生II-IV度和III-IV度aGVHD，死亡的4例患者中有3例合并有IV度aGVHD，通过单因素分析没有发现III-IV度aGVHD的危险因素。累计有4 (8.1%)例患者发生cGVHD，广泛型和局限型GVHD各2例。其余的常见并发症包括原发性植入功能不良、可逆性后部脑病综合征和出血性膀胱炎分别有2例(3.8%)，3例(5.8%)和7例(13.5%)。最常见的病毒感染是巨细胞病毒(CMV)感染，共12例(23.1%)患者，其中4例(7.8%)患者进展为CMV肠炎。我们发现II-IV度aGVHD (P = 0.001)和III-IV度aGVHD (P < 0.001)是CMV感染的危险因素。结论：allo-HSCT治疗儿童SAA有不错的疗效，但移植后相关并发症仍然是影响患者预后的主要因素之一。
Abstract: Objective: To analyze the clinical features of SAA children undergoing allo-HSCT. Methods: The clinical data of 52 SAA children (≤14 years old) who received allo-HSCT in the People’s Hospital of Xinjiang Uygur Autonomous Region from September 2017 to May 2019 were analyzed. Results: There was no significant difference in overall survival between HID-HSCT and MSD-HSCT (88.6% vs 100.0%, P = 0.154). The most common complication was graft-versus-host disease (GVHD), with grade II-IV and III-IV aGVHD occurring in 14 patients (26.9%) and 9 patients (17.3%), respectively. Among the 4 patients who died, 3 patients had grade IV aGVHD. No risk factors for grade III-IV aGVHD were found by single factor analysis. There were 4 (8.1%) patients with cGVHD, 2 patients with extensive GVHD and 2 patients with localized GVHD. Other common complications included primary poor graft function, posterior reversible encephalopathy syndrome, PRES, and hemorrhagic cystitis had 2 (3.8%), 3 (5.8%), and 7 (13.5%) cases, respectively. The most common viral infection was cytomegalovirus (CMV) activation, with 12 patients (23.1%), of whom 4 patients (7.8%) progressed to CMV enteritis. We found that grade II-IV aGVHD (P = 0.001) and grade III-IV aGVHD (P < 0.001) were risk factors for CMV activation. Conclusion: Allo-HSCT has good efficacy in pediatric SAA, but post-transplant related complications remain one of the main factors affecting patient outcomes.
文章引用：王如民, 李雪国, 徐艳芳, 高媛, 毛敏, 郎涛. 异基因造血干细胞移植治疗儿童重型再生障碍性贫血相关并发症的临床研究[J]. 临床医学进展, 2024, 14(3): 2032-2041. https://doi.org/10.12677/acm.2024.143940

参考文献

[1] Young, N.S. (2018) Aplastic Anemia. The New England Journal of Medicined, 379, 1643-1656. [Google Scholar] [CrossRef] 
[2] Liu, L., Zhang, Y., Jiao, W., et al. (2020) Comparison of Efficacy and Health-Related Quality of Life of First-Line Haploidentical Hematopoietic Stem Cell Transplantation with Unrelated Cord Blood Infusion and First-Line Immunosuppressive Therapy for Acquired Severe Aplastic Anemia. Leukemia, 34, 3359-3369. [Google Scholar] [CrossRef] [PubMed]
[3] Yang, S., Yuan, X., Ma, R., et al. (2019) Comparison of Outcomes of Frontline Immunosuppressive Therapy and Frontline Haploidentical Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia Who Lack an HLA-Matched Sibling Donor. Biology of Blood and Marrow Transplantation, 25, 975-980. [Google Scholar] [CrossRef] [PubMed]
[4] 徐佳伟, 金润铭. 儿童再生障碍性贫血造血干细胞移植相关并发症[J]. 临床儿科杂志, 2023, 41(3): 175-180.
[5] Zhang, Y., Huo, J., Liu, L., et al. (2022) Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients with Acquired Aplastic Anemia. Frontiers in Immunology, 13, Article 837335. [Google Scholar] [CrossRef] [PubMed]
[6] 付蓉, 刘春燕. 再生障碍性贫血诊断与治疗中国专家共识(2017版)解读[J]. 临床血液学杂志, 2017, 30(11): 821-825.
[7] Ferrara, J.L., Levine, J.E., Reddy, P., et al. (2009) Graft-versus-Host Disease. The Lancet, 373, 1550-1561. [Google Scholar] [CrossRef] 
[8] 韩明哲. 异基因造血干细胞移植后植入功能不良研究进展[J]. 临床血液学杂志, 2019, 32(9): 660-664.
[9] Wake, K., Imataka, G., Ohnishi, T., et al. (2020) A Case-Study of a Child with Reversible Posterior Leukoencephalopathy Syndrome (RPLS) Associated with Severe Burns throughout the Body. Iranian Journal of Public Health, 49, 1390-1391. [Google Scholar] [CrossRef] [PubMed]
[10] Galli, E., Sorà, F., Di Gianfrancesco, L., et al. (2022) Hemorrhagic Cystitis in Allogeneic Stem Cell Transplantation: A Role for Age and Prostatic Hyperplasia. Supportive Care in Cancer, 30, 4953-4959. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, Y.Y., Mo, W.J., Zuo, Y.Y., et al. (2020) Comparable Survival Outcome between Transplantation from Haploidentical Donor and Matched Related Donor or Unrelated Donor for Severe Aplastic Anemia Patients Aged 40 Years and Older: A Retrospective Multicenter Cohort Study. Clinical Transplantation, 34, e13810. [Google Scholar] [CrossRef] [PubMed]
[12] Lu, Y., Sun, R.J., Zhao, Y.L., et al. (2018) Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable with Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 24, 1881-1887. [Google Scholar] [CrossRef] [PubMed]
[13] Aladağ, E., Kelkitli, E. and Göker, H. (2020) Acute Graft-versus-Host Disease: A Brief Review. Turkish Journal of Hematology, 37, 1-4. [Google Scholar] [CrossRef] [PubMed]
[14] Adhikari, J., Sharma, P. and Bhatt, V.R. (2016) Optimal Graft Source for Allogeneic Hematopoietic Stem Cell Transplant: Bone Marrow or Peripheral Blood? Future Oncology, 12, 1823-1832. [Google Scholar] [CrossRef] [PubMed]
[15] Xu, L.P., Xu, Z.L., Wang, S.Q., et al. (2022) Long-Term Follow-Up of Haploidentical Transplantation in Relapsed/Refractory Severe Aplastic Anemia: A Multicenter Prospective Study. Science Bulletin (Beijing), 67, 963-970. [Google Scholar] [CrossRef] [PubMed]
[16] Lee, K.H., Lee, J.H., Choi, S.J., et al. (2004) Failure of Trilineage Blood Cell Reconstitution after Initial Neutrophil Engraftment in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation—Frequency and Outcomes. Bone Marrow Transplantation, 33, 729-734. [Google Scholar] [CrossRef] [PubMed]
[17] Alchalby, H., Yunus, D.R., Zabelina, T., et al. (2016) Incidence and Risk Factors of Poor Graft Function after Allogeneic Stem Cell Transplantation for Myelofibrosis. Bone Marrow Transplantation, 51, 1223-1227. [Google Scholar] [CrossRef] [PubMed]
[18] Sun, Y.Q., Wang, Y., Zhang, X.H., et al. (2019) Virus Reactivation and Low Dose of CD34 Cell, Rather than Haploidentical Transplantation, Were Associated with Secondary Poor Graft Function within the First 100 Days after Allogeneic Stem Cell Transplantation. Annals of Hematology, 98, 1877-1883. [Google Scholar] [CrossRef] [PubMed]
[19] Zhao, Y., Gao, F., Shi, J., et al. (2019) Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 25, 1898-1907. [Google Scholar] [CrossRef] [PubMed]
[20] Arcuri, L.J., Nabhan, S.K., Cunha, R., et al. (2020) Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 26, 2311-2317. [Google Scholar] [CrossRef] [PubMed]
[21] Malki, M.M, A., Song, J.Y., Yang, D., et al. (2020) Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 26, 1697-1703. [Google Scholar] [CrossRef] [PubMed]
[22] Tenneti, P., Chojecki, A. and Knovich, M.A. (2021) Iron Overload in the HCT Patient: A Review. Bone Marrow Transplantation, 56, 1794-1804. [Google Scholar] [CrossRef] [PubMed]
[23] Zama, D., Gasperini, P., Berger, M., et al. (2018) A Survey on Hematology-Oncology Pediatric AIEOP Centres: The Challenge of Posterior Reversible Encephalopathy Syndrome. European Journal of Haematology, 100, 75-82. [Google Scholar] [CrossRef] [PubMed]
[24] Cordelli, D.M., Masetti, R., Bernardi, B., et al. (2012) Status Epilepticus as a Main Manifestation of Posterior Reversible Encephalopathy Syndrome after Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer, 58, 785-790. [Google Scholar] [CrossRef] [PubMed]
[25] D’Amico, M.J., Foss, H., Uhr, A., et al. (2022) Hemorrhagic Cystitis: A Review of the Literature and Treatment Options. The Canadian Journal of Urology, 29, 11276-11283.
[26] Almalag, H.M., Alasmari, S.S., Alrayes, M.H., et al. (2021) Incidence of Hemorrhagic Cystitis after Cyclophosphamide Therapy with or Without Mesna: A Cohort Study and Comprehensive Literature Review. Journal of Oncology Pharmacy Practice, 27, 340-349. [Google Scholar] [CrossRef] [PubMed]
[27] Hayden, R.T., Gu, Z., Liu, W., et al. (2015) Risk Factors for Hemorrhagic Cystitis in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplant Infectious Disease, 17, 234-241. [Google Scholar] [CrossRef] [PubMed]
[28] Fuji, S., Einsele, H. and Kapp, M. (2017) Cytomegalovirus Disease in Hematopoietic Stem Cell Transplant Patients: Current and Future Therapeutic Options. Current Opinion in Infectious Diseases, 30, 372-376. [Google Scholar] [CrossRef] 
[29] Hosseini-Moghaddam, S.M., Rotstein, C. and Husain, S. (2011) Effects of the Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease in Organ Transplant Recipients. American Journal of Transplantation, 11, 407. [Google Scholar] [CrossRef] [PubMed]
[30] Duan, Z., Zhang, X., Liu, Y., et al. (2022) Risk Factors and Survival of Refractory Cytomegalovirus Reactivation after Allogeneic Peripheral Blood Stem Cell Transplantation. Journal of Global Antimicrobial Resistance, 31, 279-285. [Google Scholar] [CrossRef] [PubMed]

为你推荐